Industry: Biopharma / Rare Disease
Engagement Type: Corporate Narrative & Digital Repositioning
Background
A leader in rare disease treatment needed to balance its investor-focused content with a more patient- and clinician-centric narrative to better engage stakeholders across the healthcare ecosystem.
Problem
Corporate messaging emphasized financial updates, overshadowing stories of patient impact and scientific leadership. Social engagement was limited, particularly among advocacy and clinical communities.
Solution
Ringer Sciences conducted a digital audit covering web, social, and media presence. The analysis informed a repositioning strategy that included new messaging pillars, earned media targeting, SEO optimization, and stakeholder-specific content recommendations.
Results
- Balanced investor and patient storytelling with updated messaging pillars and content themes.
- Increased engagement across patient and HCP audiences through targeted digital repositioning.
- Refined all major web and press content to better reflect the company’s mission and patient impact.
- Boosted search visibility and share of voice through optimized content and earned media targeting.
Outcome
Realigned the corporate narrative to more effectively engage patients, healthcare professionals, and advocates, strengthening brand trust and visibility across digital channels.
